These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

236 related articles for article (PubMed ID: 39050801)

  • 1. Evaluating the Therapeutic Potential of Ublituximab in the Treatment of MS: Design, Development and Place in Therapy.
    Martin SJ; Guenette M; Oh J
    Drug Des Devel Ther; 2024; 18():3025-3042. PubMed ID: 39050801
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Milestone in Multiple Sclerosis Therapy: Monoclonal Antibodies Against CD20-Yet Progress Continues.
    Frisch ES; Pretzsch R; Weber MS
    Neurotherapeutics; 2021 Jul; 18(3):1602-1622. PubMed ID: 33880738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. CD20 monoclonal antibodies for the treatment of multiple sclerosis: up-to-date.
    Ancau M; Berthele A; Hemmer B
    Expert Opin Biol Ther; 2019 Aug; 19(8):829-843. PubMed ID: 31027436
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ublituximab: A new FDA-approved anti-CD20 mAb for relapsing forms of multiple sclerosis.
    Boldrini VO; Mader S; Kümpfel T; Meinl E
    Mult Scler Relat Disord; 2023 Jul; 75():104733. PubMed ID: 37156035
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Ublituximab-xiiy as a treatment option for relapsing multiple sclerosis.
    Jakimovski D; Weinstock-Guttman B; Zivadinov R
    Expert Rev Neurother; 2023; 23(12):1053-1061. PubMed ID: 37842819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Anti-CD20 Monoclonal Antibodies for Relapsing and Progressive Multiple Sclerosis.
    Sellebjerg F; Blinkenberg M; Sorensen PS
    CNS Drugs; 2020 Mar; 34(3):269-280. PubMed ID: 31994023
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Anti-CD20 therapies in multiple sclerosis: From pathology to the clinic.
    de Sèze J; Maillart E; Gueguen A; Laplaud DA; Michel L; Thouvenot E; Zephir H; Zimmer L; Biotti D; Liblau R
    Front Immunol; 2023; 14():1004795. PubMed ID: 37033984
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B cell depletion in the treatment of multiple sclerosis.
    Myhr KM; Torkildsen Ø; Lossius A; Bø L; Holmøy T
    Expert Opin Biol Ther; 2019 Mar; 19(3):261-271. PubMed ID: 30632834
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Ocrelizumab and Other CD20
    Gelfand JM; Cree BAC; Hauser SL
    Neurotherapeutics; 2017 Oct; 14(4):835-841. PubMed ID: 28695471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Preclinical study of Ublituximab, a Glycoengineered anti-human CD20 antibody, in murine models of primary cerebral and intraocular B-cell lymphomas.
    Ben Abdelwahed R; Donnou S; Ouakrim H; Crozet L; Cosette J; Jacquet A; Tourais I; Fournès B; Gillard Bocquet M; Miloudi A; Touitou V; Daussy C; Naud MC; Fridman WH; Sautès-Fridman C; Urbain R; Fisson S
    Invest Ophthalmol Vis Sci; 2013 May; 54(5):3657-65. PubMed ID: 23611989
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ublituximab: First Approval.
    Lee A
    Drugs; 2023 Apr; 83(5):455-459. PubMed ID: 36920653
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Drugs in clinical development for multiple sclerosis: focusing on anti-CD20 antibodies.
    Gasperini C; Haggiag S; Ruggieri S
    Expert Opin Investig Drugs; 2013 Oct; 22(10):1243-53. PubMed ID: 23855792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cell depletion with ublituximab reshapes the T cell profile in multiple sclerosis patients.
    Lovett-Racke AE; Gormley M; Liu Y; Yang Y; Graham C; Wray S; Racke MK; Shubin R; Twyman C; Alvarez E; Bass A; Eubanks JL; Fox E
    J Neuroimmunol; 2019 Jul; 332():187-197. PubMed ID: 31077854
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Placing CD20-targeted B cell depletion in multiple sclerosis therapeutic scenario: Present and future perspectives.
    D'Amico E; Zanghì A; Gastaldi M; Patti F; Zappia M; Franciotta D
    Autoimmun Rev; 2019 Jul; 18(7):665-672. PubMed ID: 31059839
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Therapies for multiple sclerosis targeting B cells.
    Milo R
    Croat Med J; 2019 Apr; 60(2):87-98. PubMed ID: 31044580
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase 2 multicenter study of ublituximab, a novel glycoengineered anti-CD20 monoclonal antibody, in patients with relapsing forms of multiple sclerosis.
    Fox E; Lovett-Racke AE; Gormley M; Liu Y; Petracca M; Cocozza S; Shubin R; Wray S; Weiss MS; Bosco JA; Power SA; Mok K; Inglese M
    Mult Scler; 2021 Mar; 27(3):420-429. PubMed ID: 32351164
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting B Cells to Modify MS, NMOSD, and MOGAD: Part 1.
    Graf J; Mares J; Barnett M; Aktas O; Albrecht P; Zamvil SS; Hartung HP
    Neurol Neuroimmunol Neuroinflamm; 2021 Jan; 8(1):. PubMed ID: 33406479
    [TBL] [Abstract][Full Text] [Related]  

  • 18. B Cell-Directed Therapeutics in Multiple Sclerosis: Rationale and Clinical Evidence.
    Kinzel S; Weber MS
    CNS Drugs; 2016 Dec; 30(12):1137-1148. PubMed ID: 27844213
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of multiple sclerosis with anti-CD20 antibodies.
    Barun B; Bar-Or A
    Clin Immunol; 2012 Jan; 142(1):31-7. PubMed ID: 21555250
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical Perspectives on the Molecular and Pharmacological Attributes of Anti-CD20 Therapies for Multiple Sclerosis.
    Bar-Or A; O'Brien SM; Sweeney ML; Fox EJ; Cohen JA
    CNS Drugs; 2021 Sep; 35(9):985-997. PubMed ID: 34370283
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.